Q2 2025 Management View John Charles Jacobs, President and CEO, highlighted strong progress during Q2, stating the company "continue[s] to execute on our strategy to expand access to our proven ...

U.S. ​​Health Secretary Robert F. Kennedy Jr. cut nearly $500 million in federal funding for mRNA vaccine research on Tuesday ...

On Wednesday, Novavax Inc. (NASDAQ:NVAX) reported second-quarter 2025 sales of $239.24 million, compared to $415 million a year ago, beating the consensus of $156.29 million. The company completed the ...